Our findings underscore that the HUR/MAPKAPK3 axis is a key downstream of TSPO, and targeting this axis may be a potential strategy for blocking the effects of TSPO, contributing to glioma therapy. This evidence concerns the gene MAPKAPK3 and central nervous system cancer.